Many new gene therapy treatments aren’t as profitable as predicted. But the reasons why don’t quite fit Goldman Sachs’ warning ...

Edison Investment Research said oncology still offers “continued opportunities” across immuno-oncology, targeted therapies ...

The majority of Americans do not live in a biotech hub. Yet 62 percent of all U.S. biopharma venture investment occurs in Massachusetts and California, according to Pitchbook, while 77 percent of ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems ...

The BIO campaign warns that decreased funding could hamper both current patient care and the future pipeline of medical breakthroughs. By featuring documentary-style stories of researchers and ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Many cell therapy outfits have struggled this year, with numerous companies resorting to downsizing or shutting down entirely. (iStock / Getty Images Plus) One of the top fundraisers of 2024 is ...

This new book by the National Research Council recommends that the government expand existing regulations and rely on self-governance by scientists rather than adopt intrusive new policies. One key ...

The Nature Index tracks primary research articles from 178 applied, health, natural and social sciences journals, across many different publishers, chosen by an independent group of researchers. The ...

B.C.’s globally competitive biotech sector is pushing forward with more UBC-spin-off companies that harness both research and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Behind the scenes of Southern ...